|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
61,390,000 |
Market
Cap: |
410.09(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$6.15 - $24.1 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Replimune Group is a clinical-stage biotechnology company focused on applying its capabilities in the field of oncolytic immunotherapy to transform the lives of cancer patients through its tumor-directed oncolytic immunotherapies. Co.'s RPx product candidates in its development pipeline include: RP1, which is a selectively replicating version of herpes simplex virus 1 that expresses GALV-GP R(-) and human GM-CSF; RP2, which expresses an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which expresses immune-activating proteins that stimulate T cells, in addition to anti-CTLA-4 and GALV-GP R(-).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
12,568 |
159,192 |
218,988 |
Total Sell Value |
$0 |
$137,243 |
$3,016,052 |
$4,045,075 |
Total People Sold |
0 |
2 |
9 |
9 |
Total Sell Transactions |
0 |
2 |
17 |
25 |
End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Esposito Pamela |
Chief Business Officer |
|
2021-07-15 |
4 |
AS |
$33.37 |
$153,502 |
D/D |
(4,600) |
210,159 |
|
6% |
|
Esposito Pamela |
Chief Business Officer |
|
2021-07-15 |
4 |
OE |
$1.01 |
$4,646 |
D/D |
4,600 |
214,759 |
|
- |
|
Love Colin |
Chief Operating Officer |
|
2021-07-15 |
4 |
AS |
$32.02 |
$960,600 |
D/D |
(30,000) |
835,809 |
|
6% |
|
Coffin Robert |
President & Chief R&D Officer |
|
2021-07-02 |
4 |
AS |
$40.04 |
$312,712 |
D/D |
(7,810) |
1,775,684 |
|
-16% |
|
Coffin Robert |
President & Chief R&D Officer |
|
2021-06-29 |
4 |
AS |
$40.05 |
$914,181 |
D/D |
(22,826) |
1,783,494 |
|
-15% |
|
Coffin Robert |
President & Chief R&D Officer |
|
2021-06-28 |
4 |
AS |
$40.04 |
$587,107 |
D/D |
(14,663) |
1,806,320 |
|
-16% |
|
Lewis Tanya |
Chief Dev. Oper. Off. |
|
2021-05-10 |
4 |
A |
$0.00 |
$0 |
D/D |
73,333 |
73,333 |
|
- |
|
Patel Sushil |
Chief Commercial Officer |
|
2021-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
88,333 |
88,333 |
|
- |
|
Love Colin |
Chief Operating Officer |
|
2021-04-15 |
4 |
AS |
$29.98 |
$918,783 |
D/D |
(30,000) |
895,809 |
|
0% |
|
Love Colin |
Chief Operating Officer |
|
2021-03-15 |
4 |
AS |
$32.67 |
$1,006,106 |
D/D |
(30,000) |
886,524 |
|
-3% |
|
Love Colin |
Chief Operating Officer |
|
2021-02-16 |
4 |
AS |
$35.84 |
$1,089,537 |
D/D |
(30,000) |
916,524 |
|
5% |
|
Stampacchia Otello |
Director |
|
2021-02-08 |
4 |
AS |
$45.00 |
$236,205 |
D/D |
(5,249) |
5,141,321 |
|
-18% |
|
Rhodes Jason P |
Director |
|
2021-01-26 |
4 |
AS |
$46.14 |
$256,446 |
I/I |
(5,558) |
946,000 |
|
-18% |
|
Stampacchia Otello |
Director |
|
2021-01-26 |
4 |
AS |
$45.34 |
$1,378,444 |
D/D |
(30,350) |
5,283,682 |
|
-18% |
|
Coffin Robert |
President & Chief R&D Officer |
|
2021-01-22 |
4 |
AS |
$43.99 |
$2,665,973 |
D/D |
(60,000) |
1,744,118 |
|
-28% |
|
Stampacchia Otello |
Director |
|
2021-01-22 |
4 |
AS |
$45.03 |
$511,658 |
D/D |
(11,359) |
5,314,032 |
|
-28% |
|
Love Colin |
Chief Operating Officer |
|
2021-01-19 |
4 |
AS |
$42.38 |
$333,589 |
D/D |
(7,857) |
946,524 |
|
-9% |
|
Astley-Sparke Philip |
Chief Executive Officer |
|
2021-01-19 |
4 |
AS |
$42.40 |
$358,117 |
D/D |
(8,432) |
1,255,297 |
|
-9% |
|
Esposito Pamela |
Chief Business Officer |
|
2021-01-19 |
4 |
AS |
$42.38 |
$243,226 |
D/D |
(5,727) |
175,994 |
|
-9% |
|
Esposito Pamela |
Chief Business Officer |
|
2021-01-19 |
4 |
OE |
$1.01 |
$5,784 |
D/D |
5,727 |
181,721 |
|
- |
|
Love Colin |
Chief Operating Officer |
|
2021-01-15 |
4 |
AS |
$43.07 |
$963,476 |
D/D |
(22,143) |
954,381 |
|
-11% |
|
Astley-Sparke Philip |
Chief Executive Officer |
|
2021-01-15 |
4 |
AS |
$43.02 |
$719,059 |
D/D |
(16,568) |
1,263,729 |
|
-11% |
|
Esposito Pamela |
Chief Business Officer |
|
2021-01-15 |
4 |
AS |
$43.58 |
$1,275,717 |
D/D |
(29,273) |
175,994 |
|
-11% |
|
Esposito Pamela |
Chief Business Officer |
|
2021-01-15 |
4 |
OE |
$1.01 |
$29,566 |
D/D |
29,273 |
205,267 |
|
- |
|
Stampacchia Otello |
Director |
|
2021-01-15 |
4 |
AS |
$45.19 |
$86,584 |
D/D |
(1,916) |
5,325,391 |
|
-11% |
|
172 Records found
|
|
Page 4 of 7 |
|
|